Cargando…

Reprogramming Tumor-Immune Cell Interface in Solid and Hematological Malignancies to Enhance Response to Therapy

Detalles Bibliográficos
Autores principales:	Di Martino, Maria Teresa, Zazzeroni, Francesca, Donadelli, Massimo, Chiodoni, Claudia, Caraglia, Michele, Scotlandi, Katia, Meschini, Stefania, Leonetti, Carlo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Meeting Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838855/ https://www.ncbi.nlm.nih.gov/pubmed/29506548 http://dx.doi.org/10.1186/s13046-018-0710-x

Ejemplares similares

Cell communication and signaling: how to turn bad language into positive one
por: Chiodoni, Claudia, et al.
Publicado: (2019)

Correction to: Cell communication and signaling: how to turn bad language into positive one
por: Chiodoni, Claudia, et al.
Publicado: (2019)

From single gene analysis to single cell profiling: a new era for precision medicine
por: Di Martino, Maria Teresa, et al.
Publicado: (2020)

Molecular Testing in Hematologic Malignancies
por: Zitella, Laura J.
Publicado: (2022)

Nonlymphoma hematological malignancies in systemic lupus erythematosus
por: Lu, M, et al.
Publicado: (2012)

2019–2020 Drug Updates in Hematologic Malignancies
por: Finnes, Heidi D.
Publicado: (2021)

2018–2019 Drug Updates in Hematologic Malignancies
por: Held, Lauren
Publicado: (2020)

2020–2021 Drug Updates in Hematologic Malignancies
por: Hanna, Kirollos
Publicado: (2022)

2021–2022 Drug Updates in Hematologic Malignancies
por: Tobin, Jenni
Publicado: (2023)

Vorinostat in solid and hematologic malignancies
por: Siegel, David, et al.
Publicado: (2009)

Metabolic Reprogramming in Hematologic Malignancies: Advances and Clinical Perspectives
por: Yu, Zhuoya, et al.
Publicado: (2022)

Recent Prospective in CAR T-Based Therapy for Solid and Hematological Malignancies
por: Marei, Hany E., et al.
Publicado: (2023)

Reprogramming lipid metabolism as potential strategy for hematological malignancy therapy
por: Zhang, Leqiang, et al.
Publicado: (2022)

Overcoming Gleevec-resistance by blocking oncogene addiction in malignant hematologic cells
por: Pan, Jingxuan
Publicado: (2012)

2019 ASCO Annual Meeting Highlights for the Advanced Practitioner: Hematologic Malignancies
Publicado: (2019)

Hematologic Malignancies: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner
Publicado: (2021)

Hematologic Malignancies: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner
Publicado: (2022)

New Drug Updates in Hematologic Malignancies: CAR-T, Targeted Therapeutics, and Other Agents
por: Harvey, R. Donald
Publicado: (2018)

Hematologic Malignancies: ASCO20 Virtual Scientific Program Highlights for the Advanced Practitioner
Publicado: (2020)

Regulatory T Cells and Their Prognostic Relevance in Hematologic Malignancies
por: D'Arena, Giovanni, et al.
Publicado: (2017)

Intratumoral heterogeneity and clonal evolution in blood malignancies and solid tumors
por: Varela, Ignacio, et al.
Publicado: (2017)

Five Cases Report of Solid Tumor Synchronously with Hematologic Malignancy
por: Cui, Yuehong, et al.
Publicado: (2012)

Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors
por: Federico, Mario, et al.
Publicado: (2011)

Detection and Identification of Hematologic Malignancies and Solid Tumors by an Electrochemical Technique
por: Wang, Yujie, et al.
Publicado: (2016)

Nutritional status of children and adolescents at diagnosis of hematological and solid malignancies
por: Lemos, Priscila dos Santos Maia, et al.
Publicado: (2014)

Deciphering Tumor Niches: Lessons From Solid and Hematological Malignancies
por: Mancini, Stéphane J.C., et al.
Publicado: (2021)

Exosome-Mediated Therapeutic Strategies for Management of Solid and Hematological Malignancies
por: Allegra, Alessandro, et al.
Publicado: (2022)

Hematologic malignancies following immune checkpoint inhibition for solid tumors
por: van Eijs, Mick J. M., et al.
Publicado: (2022)

PPM1D in Solid and Hematologic Malignancies: Friend and Foe?
por: Zhang, Linda, et al.
Publicado: (2022)

T-cell immunodeficiency and reconstruction based on TCR rearrangement analysis in hematological malignancy: update from 2011 ASH annual meeting
por: Li, Yangqiu
Publicado: (2012)

Targeting Autophagy to Overcome Human Diseases
por: Condello, Maria, et al.
Publicado: (2019)

Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies
por: Ellis, Leigh, et al.
Publicado: (2010)

Population Pharmacokinetics of Glasdegib in Patients With Advanced Hematologic Malignancies and Solid Tumors
por: Lin, Swan, et al.
Publicado: (2019)

Acute Respiratory Failure in Patients with Hematologic and Solid Malignancies: Global Approach
por: Sethi, Sakshi, et al.
Publicado: (2017)

Thirty-Two Case Reports of Synchronous Hematological Malignancy and Solid Tumor
por: Liu, Sha, et al.
Publicado: (2019)

Risk of infection associated with targeted therapies for solid organ and hematological malignancies
por: Ruiz-Camps, Isabel, et al.
Publicado: (2021)

The emerging landscape of exosomal CircRNAs in solid cancers and hematological malignancies
por: Zhou, Qinfeng, et al.
Publicado: (2022)

Role of Extracellular Vesicles in Hematological Malignancies
por: Raimondo, Stefania, et al.
Publicado: (2015)

Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies
por: McBride, Ali, et al.
Publicado: (2012)

Interaction Between MDSC and NK Cells in Solid and Hematological Malignancies: Impact on HSCT
por: Tumino, Nicola, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mliet4fr5t293ci69ql21117j5